Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 4,173,216 6.400% | -794,898 (-16.00%) | Filing History |
| 2024-11-14 1:22 pm Purchase | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 6,645,474 10.300% | 646,218 (+10.77%) | Filing History |
| 2024-11-14 09:30 am Purchase | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | AVORO CAPITAL ADVISORS LLC | 7,750,000 9.990% | 3,975,000 (+105.30%) | Filing History |
| 2024-11-12 10:32 am Purchase | 2024-11-08 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 5,109,141 7.933% | 2,761,614 (+117.64%) | Filing History |
| 2024-11-08 10:52 am Sale | 2024-09-30 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 4,618,359 7.170% | -197,199 (-4.10%) | Filing History |
| 2024-08-22 4:15 pm Purchase | 2024-08-21 | 13D | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 6,001,262 9.300% | 3,556 (+0.06%) | Filing History |
| 2024-04-01 08:57 am Purchase | 2024-03-28 | 13D | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,997,706 9.800% | 1,778 (+0.03%) | Filing History |
| 2024-02-14 09:15 am Sale | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | AVORO CAPITAL ADVISORS LLC | 3,775,000 6.800% | -75,000 (-1.95%) | Filing History |
| 2024-02-13 5:08 pm Purchase | 2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 3,997,564 6.730% | 337,257 (+9.21%) | Filing History |
| 2024-02-12 10:07 am Purchase | 2024-01-31 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 5,999,256 10.100% | 658,842 (+12.34%) | Filing History |
| 2024-02-12 10:03 am Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 5,340,414 9.600% | 961,255 (+21.95%) | Filing History |
| 2024-02-09 4:03 pm Sale | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 4,968,114 8.400% | -98,811 (-1.95%) | Filing History |
| 2024-02-08 10:21 am Purchase | 2023-12-29 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 4,815,558 8.680% | 224,469 (+4.89%) | Filing History |
| 2024-01-29 3:26 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,566,611 6.400% | 231,710 (+6.95%) | Filing History |
| 2024-01-23 10:31 am Sale | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | STATE STREET CORP STT | 1,894,279 3.410% | -951,942 (-33.45%) | Filing History |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,995,928 10.800% | 3,116,103 (+108.20%) | Filing History |
| 2024-01-09 4:45 pm Purchase | 2024-01-05 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 5,831,171 9.990% | 1,138,567 (+24.26%) | Filing History |
| 2023-06-05 4:10 pm Sale | 2023-06-01 | 13D | Kymera Therapeutics, Inc. KYMR | VERTEX PHARMACEUTICALS INC VRTX | 0 0.000% | -3,151,121 (Position Closed) | Filing History |
| 2023-02-14 4:28 pm Sale | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 5,066,925 9.200% | -696,087 (-12.08%) | Filing History |
| 2023-02-14 4:27 pm Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Redmile Group LLC | 2,673,837 4.900% | 86,107 (+3.33%) | Filing History |